The US Patent and Trademark Office (USPTO) has granted a patent to Vistagen’s non-opioid oral product candidate, AV-101 for ...

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment. AV-101 (4-Cl-KYN) is ...

Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

Medically reviewed by Amy Kwan, PT Your latissimus dorsi (your "lats") is a broad, flat, triangle-shaped muscle that spans ...

Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...

It is important to add pain management to leprosy treatment protocols. This can reduce the challenges that patients face. Read on.

Gabapentinoids are increasingly prescribed as an alternative to pain medicines for nursing home residents, but the reasoning behind the prescriptions — and beliefs about efficacy and deprescribing — ...

SOUTH SAN FRANCISCO, Calif. - Vistagen Therapeutics (VTGN), a clinical-stage biopharmaceutical company with a market ...